Arcturus Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- $557.6M
- Website
- http://www.arcturusrx.com
Clinical Trials
17
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (17 trials with phase data)• Click on a phase to view related trials
Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis
- First Posted Date
- 2024-12-24
- Last Posted Date
- 2025-08-03
- Lead Sponsor
- Arcturus Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT06747858
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults
- Conditions
- Influenza, Human
- Interventions
- Biological: Control vaccine younger adultsBiological: Control vaccine older adultsOther: Placebo Vaccine
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Arcturus Therapeutics, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT06602531
A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD
- Conditions
- Ornithine Transcarbamylase DeficiencyOTC DeficiencyOTCD
- Interventions
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Arcturus Therapeutics, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT06488313
- Locations
- 🇺🇸
Uncommon Cures, Chevy Chase, Maryland, United States
Immunogenicity and Safety Study of Self-amplifying MRNA COVID-19 Vaccine Administered with Influenza Vaccines in Adults
- Conditions
- COVID-19
- Interventions
- Biological: Influenza vaccine, adjuvantedOther: Placebo
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Arcturus Therapeutics, Inc.
- Target Recruit Count
- 1499
- Registration Number
- NCT06279871
- Locations
- 🇦🇺
Paratus Clinical Canberra, Canberra, Australian Capital Territory, Australia
🇦🇺Paratus Clinical Central Coast, Central Coast, New South Wales, Australia
🇦🇺Sutherland Shire Clinical Research - Walski, Miranda, New South Wales, Australia
Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults
- Conditions
- Influenza, Human
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Arcturus Therapeutics, Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT06125691
- Locations
- 🇦🇺
Nucleus Network Brisbane Clinic, Brisbane, Queensland, Australia
🇦🇺Emeritus Research Camberwell, Melbourne, Victoria, Australia
- Prev
- 1
- 2
- 3
- Next